Business Context and Reporting Period
Company: Bioanalytical Systems, Inc. (Note: Input metadata listed "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2012
Business Overview: The Company operates in two segments: Research Services (contract laboratory research for pharmaceutical development) and Research Products (manufacturing scientific instruments for life sciences). The Company is a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2012 | Nine Months Ended June 30, 2012 | Nine Months Ended June 30, 2011 |
|---|---|---|---|
| Total Revenue | $7,186 | $21,668 | $24,991 |
| Gross Profit | $2,059 | $4,684 | $8,258 |
| Operating Income (Loss) | $(540) | $(3,547) | $1,669 |
| Net Income (Loss) | $(704) | $(4,079) | $1,211 |
| Cash and Cash Equivalents | $409 (as of June 30, 2012) | ||
| Net Cash Used in Operating Activities | |||
| Debt (Current Portion) | $6,007 (Regions Bank mortgages/note) | ||
| Debt (Revolving Line of Credit) | $1,263 outstanding of $3,000 capacity |
Amounts in thousands, except per share data.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue for the nine months ended June 30, 2012, decreased 13.3% to $21.7 million from $25.0 million in the prior year. Service revenue dropped 16.7% due to lower bioanalytical analysis and toxicology volumes, while Product revenue remained relatively flat (-1.5%).
- Profitability Reversal: The Company reported a net loss of $4.1 million for the nine-month period, compared to a net income of $1.2 million in the prior year. This was driven by revenue declines and increased operating expenses.
- Restructuring Charges: The Company incurred $687 in restructuring costs for the nine months ended June 30, 2012, related to consolidating the McMinnville, Oregon laboratory into the Indiana headquarters and personnel reductions. No such charges were recorded in the prior year.
- Liquidity Deterioration: Cash and cash equivalents decreased from $2,963 at September 30, 2011, to $409 at June 30, 2012. Net cash used in operating activities was $437, compared to $1,698 provided in the prior year.
Guidance, Outlook, Risks, and Unusual Items
- Debt Covenant Compliance: The Company was not in compliance with the fixed charge coverage covenant at June 30, 2012, due to net losses. A waiver was obtained from Regions Bank on August 13, 2012. Management expects to be out of compliance on a year-to-date basis for the fourth quarter and intends to seek another waiver. Failure to obtain waivers could accelerate debt maturity.
- Refinancing Needs: Approximately $6.0 million in debt with Regions Bank matures in November 2012. The Company intends to refinance or extend these loans. On July 12, 2012, the Company listed its West Lafayette, Indiana facility for sale ($12.5 million asking price) with the intent to lease back 80% of the space to generate proceeds for debt repayment.
- Restructuring Continuation: The Company plans to close its UK facility in the fourth quarter of fiscal 2012, anticipating additional one-time termination costs and lease payments.
- Executive Change: On July 4, 2012, the President and CEO resigned. Jacqueline M. Lemke was appointed Interim President and CEO.
- Capital Expenditure Freeze: The Company has instituted a freeze on capital expenditures until spending is supported by revenue growth.
Investor Verification Checklist
- Debt Maturity: Verify the status of the $6.0 million Regions Bank debt maturing in November 2012 and the success of the proposed sale/leaseback of the Indiana facility.
- Covenant Waivers: Confirm receipt of the necessary covenant waivers from Regions Bank for the fiscal year ending September 30, 2012, to avoid cross-defaults.
- Revenue Trends: Monitor the recovery of Service revenue, specifically bioanalytical and toxicology segments, which drove the recent decline.
- Liquidity Position: Assess the sufficiency of the $409 cash balance and $2.3 million available borrowing capacity against upcoming debt obligations and restructuring costs.
- UK Closure Costs: Track the actual costs incurred from the closure of the UK facility in the fourth quarter against current estimates.